STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0287
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Jones Jason C

(Last)

(First)

(Middle)

C/O EKSO BIONICS HOLDINGS, INC.

101 GLACIER POINT, SUITE A

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/12/2023		A		20,000⁽¹⁾⁽²⁾	A	$0	158,554⁽³⁾	D
Common Stock	06/12/2023		A		170,454⁽¹⁾⁽⁴⁾	A	$0	329,008⁽⁵⁾	D
Common Stock	01/28/2021		A		1,145	A	$0	1,145	I	By 401K
Common Stock	02/17/2022		A		3,346	A	$0	4,491	I	By 401K
Common Stock	06/12/2023		A		10,800	A	$0	15,291	I	By 401K

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting.

2. The RSU grant was approved by the Board of Directors in a meeting held on December 8, 2022, on the condition that the Issuer's stockholders approved an increase in shares available for issuance under the Issuer's Amended and Restated 2014 Equity Incentive Plan, which occurred at the Issuer's Annual Meeting on June 8, 2023, and the Issuer filed a registration statement on Form S-8 with the Securities and Exchange Commission, which occurred on June 12, 2023. 1/3 of the total number of shares of Common Stock subject to the RSUs will vest on each of December 8, 2023, 2024 and 2025, in each case subject to the Reporting Person's continuous service with the Issuer as of each vesting date.

3. Includes 80,867 unvested RSUs.

4. The RSU grant was approved by the Board of Directors in a meeting held on December 8, 2022, on the condition that the Issuer's stockholders approved an increase in shares available for issuance under the Issuer's Amended and Restated 2014 Equity Incentive Plan, which occurred at the Issuer's Annual Meeting on June 8, 2023, and the Issuer filed a registration statement on Form S-8 with the Securities and Exchange Commission, which occurred on June 12, 2023. 1/3 of the total number of shares of Common Stock subject to the RSUs will vest on each of January 3, 2024, 2025 and 2026, in each case subject to the Reporting Person's continuous service with the Issuer as of each vesting date.

5. Includes 251,141 unvested RSUs.

Remarks:

	/s/ Jerome Wong, as Attorney-in-Fact	06/15/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.